

Study on the antiviral mechanisms of lactoferrin against white spot syndrome virus

林瑋倫、張雲祥

E-mail: 322097@mail.dyu.edu.tw

ABSTRACT

White spot syndrome virus (WSSV) is an important pathogen affecting cultured shrimp. To date there is no effective method to treat this disease caused by WSSV. Lactoferrin (Lf) is a multifunctional glycoprotein that is important in immune regulation and defense mechanisms against bacteria, fungi and viruses. Our previous research demonstrated that bovine Lf (bLf) treated shrimp are resistant to WSSV infection. In the present study, experiment performed on *Autographa californica* multiple nucleopolyhedrovirus (AcMNPV) and Sf9 insect cells and showed that bLf also interferes in AcMNPV infection. BLf treatment induced high level expression of certain immune-related genes in shrimp. Immunofluorescence assays demonstrated bLf was detected both in the nucleus and on the cell surface of bLf treated Sf9 cells and the hemocytes from bLf treated shrimp. Immunoelectronmicroscopy, Far-Western blot and immunoprecipitation assays showed that the bLf was able to bind to the viral particle surface, and possibly via interaction with envelope proteins VP28. These results imply that the anti-viral effects of bLf on WSSV may be involved in multiple mechanisms, including upregulation of immune related gene expression, competing with WSSV to bind host cell surface molecules, and associating with viral particles to directly interfere in their targeting on host cells.

Keywords : White spot syndrome virus、lactoferrin、shrimp、anti-viral effects

Table of Contents

1. 前言
2. 文獻整理
2.1 台灣養殖蝦的發展
2.2 甲殼類動物病原之簡介
2.3 甲殼類動物免疫機制
3. 蝦白點症病毒
4. 乳鐵蛋白
4.2.5.1 特性分析
4.2.5.2 生物性功能
4.2.5.3 作用機制
6. 研究目的
7. 材料與方法
8. 實驗材料
8.3.1.1 牛乳鐵蛋白
備製
8.3.1.2 實驗細胞、動物和病毒
8.3.2 實驗方法
8.3.2.1 牛乳鐵蛋白於Sf9昆蟲細胞抗病毒試驗
8.3.2.1.1 牛乳鐵蛋白於Sf9昆蟲細胞的毒性分析
9. 3.2.1.2 牛乳鐵蛋白於Sf9昆蟲細胞中進行抗病毒試驗
9.3.2.1.2.1 病毒效價分析
9.3.2.2 牛乳鐵蛋白對細胞之作用分析
10. 3.2.2.1 建立血球細胞初代培養
10.3.2.2.2 細胞免疫螢光分析
10.3.2.3 牛乳鐵蛋白處理蝦體內相關免疫表現分析
11. 3.2.3.1 牛乳鐵蛋白處理之白蝦樣品
11.3.2.3.2 萃取檢體RNA
12. 3.2.3.3 反轉錄?-聚合?鏈反應 (reverse transcriptase-polymerase chain reaction, RT-PCR)
12.3.2.3.4 蝦類免疫相關基因表現分析
13. 3.2.4 牛乳鐵蛋白對白點症病毒的作用分析
13.3.2.4.1 白點症病毒液備製及人工注射方式於澳洲螯蝦 感染病毒
13.3.2.4.2 超高速離心白點症病毒純化
14. 3.2.4.3 免疫電子顯微鏡分析
14.3.2.4.4 牛乳鐵蛋白與白點症病毒結構蛋白交互作用分析
15. 3.2.4.4.1 SDS聚合醯胺膠體電泳 (Sodium dodecyl sulfate-polyacrylamide gel electrophoresis, SDS-PAGE) 分析
15.3.2.4.4.2 遠西方轉漬 (Far-western blot)
16. 3.2.4.4.3 西方轉漬 (Western blot)
17. 3.2.4.4.4 牛乳鐵蛋白和VP28交互作用之免疫沉澱分析
17. 結果與討論
19. 4.1 牛乳鐵蛋白於Sf9昆蟲細胞抗病毒試驗
19.4.1.1 牛乳鐵蛋白對Sf9昆蟲細胞的毒性分析
19.4.1.2 以不同濃度牛乳鐵蛋白於Sf9昆蟲細胞中之抗AcMNPV效用
19.4.2 牛乳鐵蛋白對細胞的作用分析
20. 4.3 牛乳鐵蛋白處理蝦體之免疫相關基因表現分析
20.4.4 牛乳鐵蛋白和白點症病毒結構性蛋白質交互作用分析
22. 4.4.1 蝦白點症病毒顆粒純化
22.4.4.2 免疫電子顯微鏡分析牛乳鐵蛋白和白點症病毒顆粒之交互作用
22.4.4.3 遠西方轉漬 (Far-Western Blot) 分析
23. 4.3.3 牛乳鐵蛋白和VP28交互作用之免疫沉澱分析
23.5. 結論
25. 參考資料
40. 附錄
46. 圖1 不同濃度的牛乳鐵蛋白於秋行軍蟲細胞株 (Sf9 cell) 中進行細胞毒性試驗
26. 圖2 不同濃度的牛乳鐵蛋白在秋行軍蟲細胞株 (Sf9 cell) 中對於AcMNPV抗病毒試驗
28. 圖3 以免疫螢光顯微鏡分析牛乳鐵蛋白 (bLf) 和Sf9細胞間的交互作用
29. 圖4 蝦血球細胞初代培養
30. 圖5 以免免疫螢光顯微鏡分析牛乳鐵蛋白 (bLf) 和蝦血球細胞間的交互作用
31. 圖6 RT-PCR分析經過0.04 mg/g蝦體重之牛乳鐵蛋白 (bLf) 處理後的白蝦幾種免疫相關基因表現，並以注射PBS的0小時為對照組
32. 圖7 利用12 % SDS PAGE分析經超高速離心機純化的蝦白點症 病毒顆粒
34. 圖8 免疫電子顯微鏡分析牛乳鐵蛋白和白點症病毒顆粒之交互作用
35. 圖9 利用Far-Western和Western Blot分析牛乳鐵蛋白和蝦白點症 病毒顆粒蛋白之間的交互作用
36. 圖10 利用SDS PAGE和Western Blot確認所使用的牛乳鐵蛋白
37. 圖11 利用免疫沉澱分析牛乳鐵蛋白和VP28之間的交互作用
38. 表1 RT-PCR分析蝦類相關免疫防禦基因引子對
39.

REFERENCES

- 1.郭光雄、宋延齡、陳秀男、廖一久、游祥平、謝大文、鐘忠勇、羅竹芳。1992。蝦。黎明文化事業股份有限公司。台北。
- 2.鄭金華，2007。無特定病原(SPF)白蝦繁養殖模式之開發與產業應用。農業生技產業季刊，48-59。
- 3.詹雲翔，2007。乳鐵蛋白應用於蝦類抗白點症病毒之研究。大葉大學分子生物科技學系碩士班論文。
- 4.陳威宇，2003。蝦白點症病毒感染後草蝦基因表現之分析。國立台灣大學

動物學研究所碩士論文。 5.Ammendolia, M. G., M. Marchetti, and F. Superti. 2007. Bovine lactoferrin prevents the entry and intercellular spread of herpes simplex virus type 1 in Green Monkey Kidney cells. *Antiviral Res* 76:252-62. 6.Andersen, J. H., H. Jenssen, and T. J. Gutteberg. 2003. Lactoferrin and lactoferricin inhibit Herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir. *Antiviral Res* 58:209-15. 7.Andersen, J. H., S. A. Osbakk, L. H. Vorland, T. Traavik, and T. J. Gutteberg. 2001. Lactoferrin and cyclic lactoferricin inhibit the entry of human cytomegalovirus into human fibroblasts. *Antiviral Res* 51:141-9. 8.Belaars, L., B. W. van der Strate, H. I. Bakker, C. Reker-Smit, A. M. van Loenen-Weemaes, F. C. Wiegmans, M. C. Harmsen, G. Molema, and D. K. Meijer. 2004. Inhibition of cytomegalovirus infection by lactoferrin in vitro and in vivo. *Antiviral Res* 63:197-208. 9.Berkhout, B., R. Floris, I. Recio, and S. Visser. 2004. The antiviral activity of the milk protein lactoferrin against the human immunodeficiency virus type 1. *Biometals* 17:291-4. 10.Berkhout, B., J. L. van Wamel, L. Beljaars, D. K. Meijer, S. Visser, and R. Floris. 2002. Characterization of the anti-HIV effects of native lactoferrin and other milk proteins and protein-derived peptides. *Antiviral Res* 55:341-55. 11.Buckley, A., A. Dawson, S. R. Moss, S. A. Hinsley, P. E. Bellamy, and E. A. Gould. 2003. Serological evidence of West Nile virus, Usutu virus and Sindbis virus infection of birds in the UK. *J Gen Virol* 84:2807-17. 12.Chen, S.N., P.S. Chang, and G.H. Kou. 1989. Observation on pathogenicity and epizootiology of *Penaeus monodon* baculovirus (MBV) in cultured shrimps in Taiwan. *Fish Pathology* 24: 189-195. 13.Cohen, M. S., J. Mao, G. T. Rasmussen, J. S. Serody, and B. E. Britigan. 1992. Interaction of lactoferrin and lipopolysaccharide (LPS): effects on the antioxidant property of lactoferrin and the ability of LPS to prime human neutrophils for enhanced superoxide formation. *J Infect Dis* 166:1375-8. 14.Dhar, A. K., R. M. Bowers, K. S. Licon, G. Veazey, and B. Read. 2009. Validation of reference genes for quantitative measurement of immune gene expression in shrimp. *Mol Immunol* 46:1688-95. 15.Dhar, A. K., J. A. Cowley, K. W. Hasson, and P. J. Walker. 2004. Genomic organization, biology, and diagnosis of Taura syndrome virus and yellowhead virus of penaeid shrimp. *Adv Virus Res* 63:353-421. 16.Drobni, P., J. Naslund, and M. Evander. 2004. Lactoferrin inhibits human papillomavirus binding and uptake in vitro. *Antiviral Res* 64:63-8. 17.Elass-Rochard, E., A. Roseanu, D. Legrand, M. Trif, V. Salmon, C. Motas, J. Montreuil, and G. Spik. 1995. Lactoferrin-lipopolysaccharide interaction: involvement of the 28-34 loop region of human lactoferrin in the high-affinity binding to *Escherichia coli* 055B5 lipopolysaccharide. *Biochem J* 312 (Pt 3):839-45. 18.Fuhrman, J. A. 1999. Marine viruses and their biogeochemical and ecological effects. *Nature* 399:541-8. 19.Hara, K., M. Ikeda, S. Saito, S. Matsumoto, K. Numata, N. Kato, K. Tanaka, and H. Sekihara. 2002. Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes. *Hepatol Res* 24:228. 20.Jiravanichpaisal, P., E. Bangyekhun, K. Soderhall, and I. Soderhall. 2001. Experimental infection of white spot syndrome virus in freshwater crayfish *Pacifastacus leniusculus*. *Dis Aquat Organ* 47:151-7. 21.Johanson, B. 1960. Isolation of an iron-containing red protein from human milk. *Acta Chem Scand* 14:510-512. 22.Johansson, M. W., P. Keyser, K. Sritunyalucksana, and K. Soderhall. 2000. Crustacean haemocyte and haematopoisis. *Aquaculture* 191: 45-52. 23.Jory, D. E., and H. M. Dixon. 1999. Shrimp white spot virus in the Western Hemisphere. *Aquac. Mag.* 25:83 – 91. 24.Krishna, R. R., R. K. Rao, and P. H. Badu. 1997. White spot disease. *World Aquac.* 12:14 – 19. 25.Lee, S. Y., and K. Soderhall. 2002. Early events in crustacean innate immunity. *Fish Shellfish Immunol* 12:421-37. 26.Leu, J. H., F. Yang, X. Zhang, X. Xu, G. H. Kou, and C. F. Lo. 2009. Whispovirus. *Curr Top Microbiol Immunol* 328:197-227. 27.Levay, P. F., and M. Viljoen. 1995. Lactoferrin: a general review. *Haematologica* 80:252-67. 28.Levy, O. 1996. Antibiotic proteins of polymorphonuclear leukocytes. *Eur J Haematol* 56:263-77. 29.Liao, I. C., T. L. Huang and K. Katsutani. 1969. A preliminary report on artificial propagation of *Penaeus monodon* Fabricius. Reports of Fish Culture Research Supported by Rockefeller Foundation. JCRR Fish Ser 8: 67-71 30.Liu, H., K. Soderhall, and P. Jiravanichpaisal. 2009. Antiviral immunity in crustaceans. *Fish Shellfish Immunol* 27:79-88. 31.Loh, P. C., L. M. Tapay, Y. Lu, and E. C. Nadala, Jr. 1997. Viral pathogens of the penaeid shrimp. *Adv Virus Res* 48:263-312. 32.Lonnerdal, B., and S. Iyer. 1995. Lactoferrin: molecular structure and biological function. *Annu Rev Nutr* 15:93-110. 33.Marchetti, M., C. Longhi, M. P. Conte, S. Pisani, P. Valenti, and L. Seganti. 1996. Lactoferrin inhibits herpes simplex virus type 1 adsorption to Vero cells. *Antiviral Res* 29:221-31. 34.Marchetti, M., S. Pisani, G. Antonini, P. Valenti, L. Seganti, and N. Orsi. 1998. Metal complexes of bovine lactoferrin inhibit in vitro replication of herpes simplex virus type 1 and 2. *Biometals* 11:89-94. 35.Masson, P. L., J. F. Heremans, and E. Schonne. 1969. Lactoferrin, an iron-binding protein in neutrophilic leukocytes. *J Exp Med* 130:643-58. 36.Metz-Boutique, M. H., J. Jolles, J. Mazurier, F. Schoentgen, D. Legrand, G. Spik, J. Montreuil, and P. Jolles. 1984. Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins. *Eur J Biochem* 145:659-76. 37.Nibbering, P. H., E. Ravensbergen, M. M. Welling, L. A. van Berkel, P. H. van Berkel, E. K. Pauwels, and J. H. Nuijens. 2001. Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria. *Infect Immun* 69:1469-76. 38.Odell, E. W., R. Sarra, M. Foxworthy, D. S. Chapple, and R. W. Evans. 1996. Antibacterial activity of peptides homologous to a loop region in human lactoferrin. *FEBS Lett* 382:175-8. 39.Reed, L.J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. *The American Journal of Hygiene* 27: 493 – 497 40.Rosenberry, B. 2004. World shrimp farming. *Shrimp News International*, San Diego, Calif. 41.Seganti, L., A. M. Di Biase, M. Marchetti, A. Pietrantoni, A. Tinari, and F. Superti. 2004. Antiviral activity of lactoferrin towards naked viruses. *Biometals* 17:295-9. 42.Soderhall, K. and L. Centrenius. 1992. Crustacean immunity. *Annu. Rev. Fish Dis.* 2:3-23. 43.Soderhall, K., and P. O. Thornqvist. 1997. Crustacean immunity--a short review. *Dev Biol Stand* 90:45-51. 44.S?rensen, M., S.P.L. S?rensen. 1939. The proteins in whey, C. R. Trav. Lab. Carlsberg 23:55-99. 45.Sugumaran, M., S. Tan, and H. L. Sun. 1996. Tyrosinase-catalyzed oxidation of 3,4-dihydroxyphenylglycine. *Arch Biochem Biophys* 329:175-80. 46.Tsai, J. M., H. C. Wang, J. H. Leu, H. H. Hsiao, A. H. Wang, G. H. Kou, and C. F. Lo. 2004. Genomic and proteomic analysis of thirty-nine structural proteins of shrimp white spot syndrome virus. *J Virol* 78:11360-70. 47.Tomita, M., H. Wakabayashi, K. Shin, K. Yamauchi, T. Yaeshima, and K. Iwatsuki. 2009. Twenty-five years of research on bovine lactoferrin applications. *Biochimie* 91:52-7. 48.Ueta, E., T. Tanida, and T. Osaki. 2001. A novel bovine lactoferrin

peptide, FKCRRWQWRM, suppresses Candida cell growth and activates neutrophils. *J Pept Res* 57:240-9. 49. Vago, C. 1966. A virus disease in Crustacea. *Nature* 209:1290. 50. van der Strate, B. W., L. Beljaars, G. Molema, M. C. Harmsen, and D. K. Meijer. 2001. Antiviral activities of lactoferrin. *Antiviral Res* 52:225-39. 51. van Hulsen, M. C., J. Witteveldt, S. Peters, N. Kloosterboer, R. Tarchini, M. Fiers, H. Sandbrink, R. K. Lankhorst, and J. M. Vlak. 2001. The white spot syndrome virus DNA genome sequence. *Virology* 286:7-22. 52. Vorland, L. H. 1999. Lactoferrin: a multifunctional glycoprotein. *APMIS* 107:971-81. 53. Weinberg, E. D. 2001. Human lactoferrin: a novel therapeutic with broad spectrum potential. *J Pharm Pharmacol* 53:1303-10. 54. Yang, F., J. He, X. Lin, Q. Li, D. Pan, X. Zhang, and X. Xu. 2001. Complete genome sequence of the shrimp white spot bacilliform virus. *J Virol* 75:11811-20. 55. Yang, F., W. Wang, R. Z. Chen, and X. Xu. 1997. A simple and efficient method for purification of prawn baculovirus DNA. *J Virol Methods* 67:1-4.